Cloning, expression, and immunogenicity of novel fusion protein of Mycobacterium tuberculosis based on ESAT-6 and truncated C-terminal fragment of HSP70

Biologicals

Volumn 39, Issue 3, 2011, Pages 143-148

  Tebianian, Majid ^a,b   Hoseini, Ahmad Zavaran ^b   Ebrahimi, Seyyed Mahmoud ^a   Memarnejadian, Arash ^c   Mokarram, Ali Rezaei ^a   Mahdavi, Mehdi ^b   Sohrabi, Nooshin ^d   Taghizadeh, Morteza ^a  

^a RAZI VACCINE AND SERUM RESEARCH INSTITUTE   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d UNIVERSITY OF TEHRAN   (Iran)

Author keywords

ESAT 6; Expression; Fusion protein; HSP70; Tuberculosis

Indexed keywords

EARLY SECRETORY ANTIGENIC TARGET 6; EARLY SECRETORY ANTIGENIC TARGET 6 HEAT SHOCK PROTEIN 70 FUSION PROTEIN; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; HYBRID PROTEIN; INTERLEUKIN 4; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL INCLUSION; CELL LYSATE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ESCHERICHIA COLI; EXPRESSION VECTOR; FEMALE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN REFOLDING; SOLUBILIZATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BASE SEQUENCE; CLONING, MOLECULAR; CYTOKINES; DNA, BACTERIAL; FEMALE; GENE EXPRESSION; GENES, BACTERIAL; HSP70 HEAT-SHOCK PROTEINS; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUS; MYCOBACTERIUM TUBERCULOSIS; PROKARYOTA;

EID: 79957509298     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2011.02.002     Document Type: Article

References (27)

1. WHO report 2009: global tuberculosis control-Epidemiology, strategy, financing 2009, World Health Organization, WHO, Geneva.
2. Andersen P., Doherty T.M. The success and failure of BCG- implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005, 3:656-662.
3. Barreto M.L., Pereira S.M., Ferreira A.A. BCG vaccine: efficacy and indications for vaccination and revaccination. J. Pediatr (Rio J) 2006, 82(3 Suppl):S45-S54.
4. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995, 346:1339-1345.
5. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271(9):698-702.
6. Nasser Eddin A., Baumann S., Kaufmann S.H. New tuberculosis vaccine approaching clinical trial: an overview. Drug Discov Today 2006, 3(2):113-119.
7. Baumann S., Nasser Eddine A., Kaufmann S.H. Progress in tuberculosis vaccine development. Curr Opin Immunol 2006, 18(4):438-448.
8. Barker L.F., Brennan M.J., Rosenstein P.K., Sadoff J.C. Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol 2009, 21:331-338.
9. Doherty T.M., Olsen A.W., Weischenfeldt J., Huygen K., D'Souza S., Kondratieva T.K. Comparative analysis of different vaccines expressing defined antigens from Mycobacterium tuberculosis. J Infect Dis 2004, 190(12):2146-2153.
10. Sable S.B., Verma I., Behera D., Khuller G.K. Human immune recognition-based multicomponent subunit vaccines against tuberculosis. Eur Respir J 2005, 25(5):902-910.
11. Brodin P., Rosenkrands I., Andersen P., Cole S.T., Brosch R. ESAT-6 proteins: protective antigens and virulence factors?. Trends Microbiol 2004, 12(11):500-508.
12. Olsen A., van Pixteren L., Okkels L., Rasmussen P., Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of Antigen 85B and ESAT-6. Infect Immun 2001, 69(5):2773-2778.
13. Brandt L., Elhay M., Rosenkrands I., Lindblad E.B., Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000, 68(2):791-795.
14. Sable S.B., Kalra M., Verma I., Khuller G.K. Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity. Clin Immunol 2007, 122(3):239-251.
15. Andersen P., Doherty T.M. TB subunit vaccines: putting the pieces together. Microbes Infect 2005, 7:911-921.
16. Suzue K., Young R.A. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J Immunol 1996, 158:873-879.
17. Udono H., Yamano T., Kawabata Y., Ueda M., Yui K. Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70. Int Immunol 2001, 13(10):1233-1242.
18. Lehner T., Wang Y., Whittall T., McGowan E., Kelly C.G., Singh M. Functional domains of HSP70 stimulate generation of cytokines and chemokines, maturation of dendritic cells and adjuvanticity. Biochem Soc Trans 2004, 32:629-632.
19. Wang Y., Whittall T., McGowan E., Younson J., Kelly C., Bergmeier L.A., et al. Identification of stimulating and inhibitory epitopes within the heat shock protein 70 molecule that modulate cytokine production and maturation of dendritic cells. J Immunol 2005 Mar 15, 174(6):3306-3316.
20. Brodin P., de Jonge M.I., Majlessi L., Leclerc C., Nilges M., Cole S.T., et al. Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity. J Biol Chem 2005, 280:33953-33959.
21. Olsen A.W., Hansen P.R., Holm A., Andersen P. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 2000, 30(6):1724-1732.
22. Ge F.F., Qiu Y.F., Gao X.F., Yang Y.W., Chen P.Y. Fusion expression of major antigenic segment of JEV E protein-hsp70 and the identification of domain acting as adjuvant in hsp70. Vet Immunol Immunopathol 2006, 113(3-4):288-296.
23. Ebrahimi S.M., Tebianian M. Heterologous expression, purification and characterization of the influenza A virus M2e gene fused to Mycobacterium tuberculosis HSP70(359-610) in prokaryotic system as a fusion protein. Mol Biol Rep 2010, 37(6):2877-2883.
24. Li X., Yang X., Li L., Liu H., Liu J. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine. Vaccine 2006, 24(16):3321-3331.
25. Yadav V., Balamurugan V., Bhanuprakash V., Sen A., Bhanot V., Venkatesan G., et al. Expression of Peste des petits ruminants virus nucleocapsid protein in prokaryotic system and its potential use as a diagnostic antigen or immunogen. J Viro Methods 2009, 162:56-63.
26. Ebrahimi S.M., Tebianian M., Aghaiypour K., Nili H., Mirjalili A. Prokaryotic expression and characterization of avian influenza A virus M2 gene as a candidate for universal recombinant vaccine against influenza A subtypes; specially H5N1 and H9N2. Mol Biol Rep 2010, 37(6):2909-2914.
27. Orme I.M., Roberts A.D., Griffin J.P., Abrams J.S. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J Immunol 1993, 151:518-525.